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Background: Lung transplantation is the treatment of choice for end-stage pulmonary disease in 
selected patients. However, severe primary graft dysfunction is a significant complication of transplant and 
requires the implantation of an extracorporeal support. The aim of the study is to evaluate the impact of 
extracorporeal membrane oxygenation (ECMO) after transplant in our center.
Methods: From January 2008 till June 2018, 195 consecutive unselected patients receiving a lung transplant 
were considered. Mean age was 49±15 years. Main indications for transplant were idiopathic pulmonary 
fibrosis in 72 patients, chronic obstructive pulmonary disease in 60 patients, and cystic fibrosis in 40 patients. 
Prior to transplant, 18 patients were on mechanical ventilation and 14 were on ECMO. 
Results: Twenty-five patients required venous-venous ECMO after transplant. Vascular disease as cause of 
transplant [relative risk (RR) 7.8, 95% CI: 1.5–41, P=0.02], donor age (RR 1.6, 95% CI: 1.03–2.3, P=0.03) 
and need for cardiopulmonary by-pass during transplant (RR 3.1, 95% CI: 1.02–9, P=0.04) were associated 
with ECMO implantation. Patients requiring post-transplant ECMO received more transfusions (P<0.01), 
had a longer mechanical ventilation (P<0.01) and ICU stay (P<0.01) and had a higher hospital mortality 
(P<0.01). Post-transplant ECMO significantly influenced one- and five-year survival [hazard ratio (HR) 5.5, 
95% CI: 3–10, P<0.001 and HR 3.5, 95% CI: 2–6, P<0.001, respectively]. However, conditional survival 
after t months is similar for patients with or without post-transplant ECMO.
Conclusions: In our experience, although ECMO is a reliable and effective strategy to support pulmonary 
function, severe graft dysfunction after lung transplantation still has a significant impact on early and late 
results.
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Introduction
Lung transplantation (LTx) is the ultimate therapy for 
selected patients with end-stage respiratory insufficiency (1,2). 
LTx is characterized by a long waiting period due to a low 
rate of lung graft suitability among the pool of available 
donors. Moreover, unstable patients can receive only 
supportive therapies such as mechanical ventilation and 
or extracorporeal oxygenation for a limited period of 
time (3,4). However, the clinical armamentarium has 
evolved in recent years. Procedures of ex-vivo lung 
perfusion (EVLP) allow a better evaluation and in some 
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cases a recondition of otherwise unusable grafts (5-7). 
Although still limited in some centers, donation after 
cardiac death (DCD) is growing with a potential increase 
of the donor pool (8). Lastly, evolution of extracorporeal 
oxygenation technologies allows a more effective and longer 
supportive therapy both pre- and post-transplant (3). The 
aim of this study is to evaluate the impact of extracorporeal 
membrane oxygenation (ECMO) in the post-transplant 
period in our center in the last ten years.
Methods
From January 2008 till June 2018, 195 consecutive LTx were 
performed at Città della Salute e della Scienza, University 
Hospital in Turin. Mean age at transplant was 49±15 
(range, 11–69) years. Mean time on the waiting list was 
256±329 (range, 1–2,402) days with a median of 141 days. 
Main indications for LTX were: idiopathic pulmonary 
fibrosis (IPF) in 72 patients (37%), chronic obstructive 
pulmonary disease (COPD) in 60 patients (31%), and cystic 
fibrosis in 40 (21%) patients. Twenty-three patients (12%) 
received a transplant on an urgent basis. According to a 
national protocol, urgent lung transplant was reserved for 
young listed patients (Age ≤50 years) requiring mechanical 
ventilation and/or extracorporeal lung support with ECMO 
or Novalung (4). 
Eighteen (9%) and 14 (7%) patients were on mechanical 
ventilation and ECMO before transplant, respectively. 
Table 1 summarizes recipients’ and donors’ characteristics. 
Lung graft has been preserved with an antegrade and 
retrograde flush with Perfadex® and cold storage at 4 ℃ 
before transplant. Thirty-two grafts considered unsuitable 
for direct transplantation underwent EVLP before 
transplant. Mean ischemic time was 376±184 (range, 
119–1,380) minutes. Lung transplant has been performed 
according to the standard technique. Cardiopulmonary 
Table 1 Baseline characteristics (195 patients)
Characteristics Value
Age at transplant, mean ± SD [range] (years) 49±15 [11–69] (median 54) 
Male sex, n [%] 123 [63] 
Waiting time on the waiting list, mean ± SD [range] (days) 256±329 [1–2,402] (median 141)
Lung disease, n [%]
Idiopathic pulmonary fibrosis 72 [37] 
COPD 60 [31] 
Cystic fibrosis 40 [21] 
Vascular diseases 9 [5] 
Others 11 [6] 
Mechanical ventilation before transplant, n [%] 18 [9] 
ECMO before transplant, n [%] 14 [7] 
Urgent LTx, n [%] 23 [12] 
Ex vivo lung perfusion, n [%] 32 [16] 
Bilateral lung transplantation, n [%] 157 [81] 
Mean ischemic time, mean ± SD [range] (min) 376±184 [376–1,380]
Donor age, mean ± SD [range] (years) 44±14 [7–69] (median 47) 
Length of donor’s mechanical ventilation, mean ± SD [range] (days) 3±2 [1–9] (median 2)
P/F ratio at 100% of O2 [range] 465±91 [209–648] (median 463)
SD, standard deviation; COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; P/F, ratio of arterial 
oxygen concentration to the fraction of inspired oxygen.
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bypass was used in case of poor oxygenation on mono-
lateral ventilation, hemodynamic instability after pulmonary 
artery clamping or in patients on extracorporeal ventilation 
before transplant. One hundred and fifty-seven patients 
(81%) received a bilateral graft. Single lung transplant has 
been performed in selected cases only on patients with 
parenchymal disease without history of infection and/or 
pulmonary hypertension. 
Statistical analysis
Descriptive statistics are presented as mean, median, 
standard deviation and ranges for the continuous variables, 
and as counts and percentages for categorical variables. 
Comparisons between groups were performed using a χ2 
test or ANOVA test as appropriate. All significant variables 
at univariate analysis were included in a Cox regression 
multivariate analysis with a stepwise forward conditional 
method. Kaplan-Meier curves were used to evaluate event-
free survival according to categorical variables, compared 
by the Mantel-Cox test. A two-sided P value <0.05 was 
considered statistically significant; all analyses were 
performed with SPSS 20.0 (IBM corp., Armonk, NY, USA).
Results
Twenty-five patients (12.8%) required venous-venous 
ECMO after transplant for a mean time of 8±8 (range, 
1–30, median 5) days. ECMO was accomplished through 
the insertion of a cannula from the left femoral vein up 
to the right atrium for the input and through a second 
cannula from the right femoral vein with the tip just 
below the junction between the inferior vena cava and the 
right atrium for drainage. After heparin administration 
(with a target activated clotting time of 200 seconds), 
cannulas were inserted under the guidance of a trans-
esophageal echocardiogram to check the correct position. 
The cannulas were then connected to an ECMO circuit 
and extracorporeal support initiated. During support, a 
protective lung ventilation protocol was applied. Cardiac 
function was also checked to identify the onset of right 
or left ventricular failure. Univariate analysis showed that 
patients requiring ECMO after transplant suffered more 
frequently from vascular disease (pulmonary hypertension 
or Eisenmenger syndrome) as cause of transplant, had 
higher pulmonary artery pressure, were more frequently 
on mechanical ventilation or on ECMO before transplant, 
required cardiopulmonary bypass during transplant more 
frequently and received a graft from an older donor (Table 2). 
Independent risk factors for post-transplant ECMO were: 
vascular disease as cause of transplant [relative risk (RR) 
7.8, 95% CI: 1.5–41, P=0.02], donor age (RR 1.6, 95% 
CI: 1.03–2.3, P=0.03) and need of cardiopulmonary bypass 
during LTx (RR 3.1, 95% CI: 1.02–9, P=0.04) (Table 3). 
Patients requiring post-transplant ECMO received 
transfusions more frequently (P<0.01), had a greater duration 
of mechanical ventilation (P<0.01) and ICU stay (P<0.01), 
and had a higher hospital mortality (P<0.01) (Table 4). 
Among the 24 patients supported with ECMO after 
LTX, in 18 (75%) patients ECMO has been weaned after 
8.8±8.9 (range, 1–30, median 5) days. Duration of ECMO 
support did not differ between weaned and not weaned 
patients (P=0.64). Hospital mortality was higher in patients 
with unsuccessful weaning (P<0.001) (Table 5). Overall 
hospital mortality was 12.3%. At univariate analysis, 
hospital mortality was influenced by the following factors: 
need for cardiopulmonary bypass during LTx (P=0.03), 
pre-transplant mechanical ventilation (P<0.01), pre-
transplant ECMO (P<0.01), urgent LTx (P<0.01) (Table 6). 
ECMO after LTx (RR 7.7, 95% CI: 2.8–21, P<0.01) and 
pre-transplant mechanical ventilation (RR 4.6, 95% CI: 
1.4–15, P<0.01) were identified as independent risk factors 
for hospital mortality (Table 7). One- and five-year survival 
rates were 73% and 48%, respectively. Post-transplant 
ECMO significantly influenced one- and five-year survival 
[hazard ratio (HR) 5.5, 95% CI: 3–10, P<0.001 and HR 3.5, 
95% CI: 2–6, P<0.001, respectively] (Figure 1). However 
conditional survival after 3 months is similar for patients 
with or without post-transplant ECMO (Figure 2).
Discussion
The present study shows our experience on consecutive 
unselected patients receiving LTx in our center during the 
last ten years. The analysis has been focused on primary 
graft dysfunction with the need for ECMO after transplant. 
Improvements in ECMO technology have led to a safer 
and more effective support of lung function either before 
and after surgery, however, post-transplant severe graft 
dysfunction (although supported by ECMO) still remains a 
significant risk factor for poor survival after LTx (9). 
The main findings of the present analysis are that 
vascular disease as an underlying cause of transplant is 
independently associated with post-transplant ECMO, and 
57Annals of cardiothoracic surgery, Vol 8, No 1 January 2019
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2019;8(1):54-61www.annalscts.com
Table 2 Univariate analysis for need of ECMO after lung transplantation
Variables ECMO after LTx (n=25) No ECMO after LTx (n=170) P value
Age at transplant, mean ± SD (years) 45±16 50±15 0.08
Male sex, n [%] 13 [52] 110 [65] 0.25
Mean waiting time on LTx list, mean ± SD (days) 327±475 245±304 0.24
Cause of lung disease, n [%] <0.01
COPD 4 [16] 56 [33]
Cystic fibrosis 5 [20] 35 [21]
Idiopathic pulmonary fibrosis 9 [36] 63 [37] 
Vascular disease 5 [20] 4 [2] 
Re-LTx 0 6 [4] 
Other causes 1 [4] 7 [4]
sPAP, mean ± SD (mmHg) 51±20 39±13 <0.01
mPAP, mean ± SD (mmHg) 36±16 25±9 <0.01
Need for CPB during transplant, n [%] 17 [68] 43 [25] <0.01
Mechanical ventilation before transplant, n [%] 6 [24] 12 [7] <0.01
ECMO before transplant, n [%] 6 [24] 8 [5] <0.01
Urgent LTx, n [%] 7 [28] 16 [9] <0.01
Donor age, mean ± SD (years) 49±10 43±14 <0.01
P/F >350 at FiO2 100%, n [%] 18 [72] 131 [77] 0.58
Ischemic time, mean ± SD (min) 399±242 374±179 0.64
ECMO, extracorporeal membrane oxygenation; LTx, lung transplant; SD, standard deviation; COPD, chronic obstructive pulmonary 
disease; sPAP, systolic pulmonary artery pressure; mPAP, mean pulmonary artery pressure; CPB, cardiopulmonary by-pass; P/F, ratio of 
arterial oxygen concentration to the fraction of inspired oxygen.
Table 3 Multivariate analysis for need of ECMO after lung transplantation
Variables RR 95% CI P value
Vascular disease as cause of transplant 7.8 1.5–41 0.02
Donor age (per 10 years increase) 1.6 1.03–2.3 0.03
Need for CPB during LTx 3.1 1.02–9 0.04
ECMO before LTx 3.3 0.8–14 0.10
Mechanical ventilation before LTx 2.0 0.2–29 0.60
Urgent LTx (n, %) 0.7 0.1–15 0.80
RR, relative risk; CI, confidence interval; CPB, cardiopulmonary by-pass; LTx, lung transplant; ECMO, extracorporeal membrane 
oxygenation.
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Table 4 Comparison of lung transplanted patients with or without need of post-transplant ECMO
Variables ECMO after LTx (n=25) No ECMO after LTx (n=170) P value
Number of transfused RBC units, median [IQR] 5 [2–11] 1 [0–3] <0.01
Length of ICU stay, median [IQR] (days) 28 [9–43.5] 6 [3–15] <0.01
Length of mechanical ventilation, median [IQR] (days) 8.2 [3.0–24.5] 1 [0.8–3] <0.01
In-hospital mortality, n [%] 11 [44] 13 [8] <0.01
IQR, interquartile range; ECMO, extracorporeal membrane oxygenation; LTx, lung transplant; RBC, red blood cells; ICU, intensive care unit.
Table 5 Univariate analysis for post-transplant ECMO weaning
Variables Successful weaning (n=18) No weaning (n=6) P value
Age at transplant, mean ± SD (years) 46±17 42±15 0.64
Waiting time on LTx list, mean ± SD (days) 233±218 586±900 0.12
Vascular disease as cause of LTx, n [%] 4 [22] 1 [17] 0.77
Need for CPB during LTx, n [%] 12 [67] 5 [83] 0.46
Mechanical ventilation at LTx, n [%] 3 [17] 3 [50] 0.11
ECMO at LTx, n [%] 3 [17] 3 [50] 0.11
Urgent LTx, n [%] 4 [22] 3 [50] 0.25
Hospital mortality, n [%] 4 [22] 6 [100] 0.001
P/F ratio at 100% of O2 >350, n [%] 12 [67] 5 [83] 0.46
Ischemic time, mean ± SD (min) 359±218 169±57 0.58
Donor age, mean ± SD (years) 50±10 50±10 0.96
SD, standard deviation; LTx, lung transplant; CPB, cardiopulmonary by-pass; ECMO, extracorporeal membrane oxygenation; P/F, ratio of 
arterial oxygen concentration to the fraction of inspired oxygen.
that ECMO support has a significant impact on early and 
late outcomes. Pulmonary hypertension is a well-known risk 
factor for severe primary graft dysfunction. This is due to 
the particular pathophysiology of pulmonary hypertension. 
High pressures in the pulmonary artery cause hypertrophy 
and enlargement of right ventricle with a normal or even 
small left ventricle. A D-shape pattern with a leftward shift 
of the inter-ventricular septum is always present. The left 
ventricle usually maintains a preserved systolic function but 
suffers from different degrees of diastolic dysfunction. After 
transplant, there is a significant decrease of right ventricular 
afterload and an important increase of left ventricular 
preload. Therefore, evaluation of left ventricular diastolic 
function is crucial in the pre-transplant phase in order to 
identify the correct surgical strategy (bilateral lung or heart 
and LTx). Intraoperative and postoperative management of 
LTx in the pulmonary hypertension setting is challenging. 
During surgery, hemodynamic instability is usually related to 
a worsening right ventricular function due to the increased 
afterload after pulmonary artery clamping. Extracorporeal 
circulatory support is therefore always needed to maintain 
hemodynamic stability. Moreover, extracorporeal support 
during transplant allows a controlled and smoother 
reperfusion phase that reaches its maximal critical point 
intra-operatively during the implantation of the second 
graft (10). After transplant, the left ventricle receives a 
huge amount of blood due to the dramatic decrease in 
right ventricular afterload. For these reasons, some centers 
suggest maintaining a venous-arterial ECMO in the 
postoperative period to allow a progressive adaptation of the 
left ventricle to the new hemodynamic condition (11-13). 
Recently, Moser et al.  from Vienna reported their 
59Annals of cardiothoracic surgery, Vol 8, No 1 January 2019
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2019;8(1):54-61www.annalscts.com
Table 6 Univariate analysis of hospital mortality
Variables Dead (n=24) Alive (n=171) P value
Age at transplant, mean ± SD (years) 53±15 49±15 0.26
Male sex, n [%] 13 [54] 110 [64] 0.37
Time on waiting list, mean ± SD (days) 313±507 248±298 0.36
Indication for LTx, n [%] 0.14
COPD 6 [25] 54 [32]
Cystic fibrosis 2 [8] 38 [22]
Idiopathic pulmonary fibrosis 13 [54] 59 [34]
Vascular disease 1 [4] 8 [5]
Other causes 1 [4] 13 [8]
sPAP, mean ± SD (mmHg) 45±17 40±15 0.10
mPAP, mean ± SD (mmHg) 30±12 26±10 0.09
Need for CPB during LTx, n [%] 12 [50] 48 [28] 0.03
Mechanical ventilation before LTx, n [%] 7 [29] 11 [6] <0.01
ECMO before LTx, n [%] 5 [21] 9 [5] <0.01
Urgent LTx, n [%] 8 [33] 15 [9] <0.01
Ischemic time, mean ± SD (min) 338±86 379±190 0.44
Donor age, mean ± SD (years) 48±16 43±14 0.13
SD, standard deviation; COPD, chronic obstructive pulmonary disease; sPAP, systolic pulmonary artery pressure; mPAP, mean pulmonary 
artery pressure; CPB, cardio-pulmonary by-pass; LTx, lung transplant; ECMO, extracorporeal membrane oxygenation.
Table 7 Multivariate analysis of hospital mortality
Variables RR 95% CI P value
ECMO after LTx 7.7 2.8–21 <0.01
Mechanical ventilation  
before LTx
4.6 1.4–15 <0.01
Donor age  
(per 10 years increase)
1.1 0.9–1.2 0.44
ECMO before LTx 0.8 0.2–4.5 0.82
Need for CPB during LTx 0.8 0.3–2.9 0.80
Urgent LTx (n, %) 2.6 0.2–33 0.57
RR, relative risk; CI, confidence interval; ECMO, extracorporeal 
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Figure 1 Kaplan-Meier survival curves stratified according to the 
need of post-transplant ECMO. ECMO, extracorporeal membrane 
oxygenation.
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experience on LTx for idiopathic pulmonary hypertension. 
They found that a prolonged venous-arterial ECMO after 
transplant provides excellent results in comparison with the 
standard management without prolonged support. They 
reported one- and five-year survival rates in the prolonged 
ECMO group of 90.2% and 87.4%, respectively (12). 
However, beside the evident benefits of this strategy, 
extracorporeal venous-arterial support exposes patients to 
complications related to the ECMO technology itself (11). 
More frequent complications (infection or leg ischemia) 
are related to the site of cannulation. Moreover, the 
most important complication of venous-arterial ECMO 
is represented by the so-called “Harlequin Syndrome”, 
characterized by a discrepancy in oxygenation between the 
upper and the lower part of the body. Harlequin syndrome 
and subsequent hypoxic brain damage must be promptly 
recognized and treated. Treatment is represented by the 
increase of ventilator support and or circulatory support 
to full flow or by the implementation of ECMO therapy 
with a venous-venous-arterial configuration. In our 
population a venous-arterial ECMO after transplant has 
never been required. In three cases (two primary pulmonary 
hypertension and one Eisenmenger syndrome patients) 
with a significant post-transplant left ventricular diastolic 
dysfunction, we used venous-venous ECMO in association 
with the insertion of an intra-aortic balloon pump (IABP). 
This strategy guarantees adequate oxygenation (maintaining 
protective or ultra-protective ventilation), reducing the risk 
of hypoxia in the upper part of the body. We acknowledge 
that IABP offers only a partial cardiac support, however, in 
our cases it was enough to allow a progressive adaptation of 
the left ventricle. We believe that this option can be applied 
in selected cases as an alternative strategy to venous-arterial 
ECMO after LTx, reserving the latter for the most critical 
patients. Early and long-term results are influenced by the 
need for post-transplant ECMO, although conditional 
survival at three months is not influenced by post-surgery 
extracorporeal support. Considering that in our series 
ECMO has been implanted as a rescue therapy for severely 
impaired pulmonary function and never as a preemptive 
strategy, our data confirm the significant impact of severe 
graft dysfunction on hospital and long-term results. 
The retrospective, single-centre design and the relatively 
small sample size are the main limitations of the study.
In conclusion, although our analysis suffers of some 
critical points represented by the relatively small cohort of 
patients and the retrospective nature of our analysis, in our 
experience, severe graft dysfunction after LTx still has a 
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